Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward

Author:

Zhao Xue-Lian,Hu Shang-Ying,Hu Jia-Wei,Wang Hong-Hao,Wen Tian-Meng,Feng Yu-Shu,Qiao You-Lin,Zhao Fang-HuiORCID,Zhang Yong

Abstract

AbstractThe human papillomavirus (HPV) vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. For more than 15 years, China has expedited a series of efforts on research and development of the domestically manufactured HPV vaccines, producing local population-based evidence, promoting free HPV vaccination from pilots, and launching action plans to tackle barriers in the scale-up of HPV vaccination. To further roll out the HPV vaccination program in China, several challenges should be addressed to support the steps forward. The availability of more locally manufactured HPV vaccines, pricing negotiation and local evidence supporting the efficacy of one-dose schedule would greatly alleviate the continued supply and financial constraints in China. Meanwhile, more attention should be paid to girls living in low-resource areas and males to ensure equal access to the HPV vaccination. Furthermore, linkage to secondary prevention and further real-world monitoring and evaluation are warranted to inform effective cervical cancer prevention strategies in the post-vaccine era. Graphical Abstract

Funder

Bill and Melinda Gates Foundation

CAMS Innovation Fund for Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Medicine

Reference23 articles.

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. 2020. https://gco.iarc.fr/today. Accessed 15 Apr 2023.

2. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. https://www.who.int/initiatives/cervical-cancer-elimination-initiative#cms. Accessed 15 Apr 2023.

3. World Health Organization. HPV vaccine included in national immunization programme. 2023. https://app.powerbi.com/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9. Accessed 15 July 2023.

4. World Health Organization. Human papillomavirus (HPV) vaccination coverage. 2023. https://immunizationdata.who.int/pages/coverage/hpv.html?CODE=Global&ANTIGEN=15HPV1_F&YEAR=. Accessed 15 July 2023.

5. National Medical Products Administrition. Registration and Information Disclosure Platform for Drug Clinical Studies. 2022. http://www.chinadrugtrials.org.cn/index.html. Accessed 16 Apr 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3